The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 14 rounds in the feed, most often in Biotech.
We look to support extraordinary founders building companies in overlooked emerging markets.
Venture capitalatlas.venturesRounds from 2011-08-22 to 2026-06-10
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Ethyreal Bio Ethyrealbio develops investigational therapies targeting Thyroid Eye Disease and Graves' Disease for patients. | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $101M | 2026-06-10 | [ LEAD ] |
Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. |
| $103M |
| 2026-01-10 |
| [ PART ] |
Diagonal Therapeutics They develop innovative clustering antibodies for the treatment of genetic diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-01-08 | [ PART ] |
Triana Biomedicines Trianabio sells novel biopharmaceutical therapeutics focused on utilizing molecular glues to treat previously undruggable diseases, primarily targeting cancer. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-12-03 | [ PART ] |
Sunflower Labs Sunflower Labs sells an AI-powered drone security system called the Beehive, designed to protect commercial, industrial, and residential properties. | Series B Verified against 1 of 4 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $16M | 2025-11-04 | [ PART ] |
AAVantgarde AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet need | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $141M | 2025-11-03 | [ PART ] |
Kailera Therapeutics Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people living with obesity | Series B Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $600M | 2025-10-14 | [ PART ] |
Diagonal Therapeutics They develop innovative clustering antibodies for the treatment of genetic diseases. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $128M | 2024-04-03 | [ LEAD ] |
AAVantgarde AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet need | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $65.2M | 2023-06-06 | [ LEAD ] |
Novartis-partnered biotech A biotechnology company pioneering the discovery of precision covalent medicines | Series A Verified against 2 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $70M | 2022-10-14 | [ PART ] |
Triana Biomedicines Trianabio sells novel biopharmaceutical therapeutics focused on utilizing molecular glues to treat previously undruggable diseases, primarily targeting cancer. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2022-04-06 | [ LEAD ] |
Kinaset Therapeutics Developing inhaled therapeutics for respiratory diseases, specifically targeting severe asthma patients. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $40M | 2020-11-30 | [ LEAD ] |
Hopper Hopper offers travel booking services for flights, hotels, rental cars, and vacation packages, targeting consumers planning trips. | Funding round Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $12M | 2012-08-15 | [ PART ] |
Hopper Hopper offers travel booking services for flights, hotels, rental cars, and vacation packages, targeting consumers planning trips. | Funding round Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $8M | 2011-08-22 | [ PART ] |